XENE — Xenon Pharmaceuticals Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1582313 · British Columbia, Canada
Last close
$38.78
Market Cap
$3.81B
52W High
$72.66
52W Low
$33.38
ADV30
1,373,895
Next earnings
2026-11-09
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -120,067,000 -110,435,000 1,199,875,000 82,560,000 53,493,000
Jun 2026 0 — -123,155,000 -110,736,000 1,295,772,000 119,527,000 53,376,000
Mar 2026 0 — -112,328,000 -102,302,000 1,386,810,000 545,867,000 48,991,000
Dec 2025 0 — -109,767,000 -105,261,000 633,163,000 199,163,000 51,403,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-356,098,000
Investing CF
$-622,631,000
Financing CF
$956,804,000
CapEx
$-1,010,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.70
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,568,853,000
Inventory
—
Receivables
$1,169,000
ST Investments
$868,238,000
EBIT TTM
$-465,317,000
Pretax Income TTM
$-429,509,000
Interest Exp TTM
—
Analysts
16

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
$-462,999,008
Free Cash Flow
$-209,309,120
Enterprise Value
$3,033,777,152
Total Cash
$950,798,016
Total Debt
$6,009,000
Shares Out
98,284,734
Trailing EPS
$-4.69
Book Value
$11.66
ROE
-50.3%
ROA
-32.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,500,000 -373,070,000 -345,910,000 633,163,000 51,403,000 581,760,000 -279,118,000
Dec 2024 0 -279,298,000 -234,330,000 798,139,000 43,236,000 754,903,000 -181,389,000
Dec 2023 0 -214,054,000 -182,393,000 964,798,000 36,877,000 927,921,000 -151,112,000
Dec 2022 9,434,000 -129,143,000 -125,373,000 754,146,000 32,649,000 721,497,000 -101,028,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-409,195,000
OpCashFlow TTM
—
Assets (Latest)
$1,295,772,000
Forward EPS
$-4.63

Max Pain — expiry 2027-01-15

max pain strike: $40.00 · spot: $37.75 · call oi: 6,878 · put oi: 648
Expected Move to 2027-01-15: ±$7.70 (20.40%) — implied range $30.05 – $45.45 · ATM straddle on $37.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TNGX Tango Therapeutics, Inc. $3.75B $22.11 —
SLS SELLAS Life Sciences Group, Inc. $3.90B $19.15 —
OGN Organon & Co. $3.65B $13.90 —
ABCL AbCellera Biologics Inc. $3.60B $11.03 —
AMLX Amylyx Pharmaceuticals, Inc. $3.54B $27.52 —

News headlines (Yahoo Finance, 1h cache)

Xenon Stock Rises 12% in the Past Month on Pipeline Progress
2026-11-17 15:11 · Yahoo
Xenon Pharmaceuticals Inc. Q3 2026 Earnings Call Summary
2026-11-10 13:30 · Yahoo
Xenon Pharmaceuticals Inc (XENE) (Q3 2026) Earnings Call Highlights: $1. ...
2026-11-10 05:11 · Yahoo
Xenon Pharmaceuticals Q3 Earnings Call Highlights
2026-11-10 03:14 · Yahoo
Is Xenon Pharmaceuticals (XENE) Above Fair Value After Phase 2 Progress?
2026-11-10 00:20 · Yahoo
Xenon Pharmaceuticals: Q3 Earnings Snapshot
2026-11-09 21:13 · Yahoo
Xenon to Present at Upcoming Investor Conferences
2026-11-03 21:01 · Yahoo
Xenon to Report Q3 2026 Financial Results on November 9, 2026
2026-11-02 21:01 · Yahoo
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-30 20:01 · Yahoo
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
2026-10-29 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.